Inside information filing with the CSRC in relation to the proposed implementation of h share full circulation
Filed with HKEX · Stock code 6887 · · 2 pages · English
Summary by 6ix AI
This filing is an inside information announcement regarding the proposed implementation of H Share full circulation by Sunshine Lake Pharma Co., Ltd.. The company has submitted an application to the China Securities Regulatory Commission for the conversion of domestic shares into H shares. This conversion represents a portion of the company's total issued share capital and is subject to regulatory approvals. Further announcements will be made regarding the progress of this application as required by the listing rules.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sunshine Lake Pharma Co., Ltd. on 6ix
Earlier from Sunshine Lake Pharma
- Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA™ an Interchangeable Biosimilar of Lantus® (insulin glargine)
- Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
Later from Sunshine Lake Pharma
- Next Day Disclosure Return
- Interim Report 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement Insulin Degludec and Insulin Aspart Injection obtained marketing approval from the china national medical products administration
- Change of company secretary, authorized representative and process agent
Follow Sunshine Lake Pharma into a list and get an email when it puts out news.
Follow Sunshine Lake Pharma